TY - JOUR T1 - Complications of Percutaneous Radiofrequency Thermal Ablation of Primary and Secondary Lesions of the Liver JF - Anticancer Research JO - Anticancer Res SP - 2911 LP - 2916 VL - 27 IS - 4C AU - GUIDO POGGI AU - ALBERTO RICCARDI AU - PIETRO QUARETTI AU - CRISTINA TERAGNI AU - ANGELO DELMONTE AU - ALESSIO AMATU AU - GAIA SAINI AU - MAURO MAZZUCCO AU - ANTONIO BERNARDO AU - RAFFAELLA PALUMBO AU - ANDREA CANTO AU - SIMONE BERNIERI AU - GIOVANNI BERNARDO Y1 - 2007/07/01 UR - http://ar.iiarjournals.org/content/27/4C/2911.abstract N2 - Hepatocellular carcinoma is one of the most common malignancies in the world, with the liver being the second most frequently involved organ in metastatic disease. Although the gold standard treatment for malignant liver disease is surgical resection, only few patients can undergo such an intervention. This explains the current great interest in various loco-regional therapies, of which radiofrequency thermal ablation (RFA) is the most common. To date, only a few studies have evaluated the complications associated with this treatment. The aim of this study was to determine the rate of complications, divided into major and minor, in patients treated with RFA. A total of 373 hepatic lesions in 250 patients were treated with 292 sessions of percutaneous ultrasound-guided RFA. According to our data, ten patients (4%) had major complications, twelve patients (4.8%) had minor complications, no deaths occurred. Around 30% of patients had a body temperature increase of up to 38ÆC. All complications, except one, were treated with non-surgical therapies. One patient with massive hemoperitoneum required surgery. In conclusion, percutaneous RFA is a loco-regional therapy associated with a low incidence of side-effects and a negligible risk of death. ER -